India · Delayed Price · Currency is INR Quick Heal Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Revenue declined and losses deepened amid a strategic shift from B2C antivirus to enterprise cybersecurity, with enterprise now over 50% of revenue. Management expects the transition to last up to two more quarters, with a strong focus on AI, R&D, and international growth.
-
Q2 FY26 delivered strong revenue and margin growth, led by seasonal consumer strength and robust enterprise momentum. Enterprise is set to overtake consumer as the main revenue driver, with new products and government demand fueling future growth.
-
Q1 FY 2026 saw revenue decline to ₹57 crore due to consumer softness and deferred enterprise deals, with EBITDA at -₹9.7 crore. Strategic investments in innovation, international growth, and a healthy order book position the company for future recovery.
Fiscal Year 2025
-
FY25 saw revenue decline to INR 280 crore and negative EBITDA, driven by consumer headwinds and delayed government deals, but enterprise and cloud segments grew to 40% and 31% of revenue, respectively. Multiple new products launched, with a strong pipeline and order book supporting a positive FY26 outlook.
-
Q3 FY25 saw a 14% YoY revenue decline due to consumer and government headwinds, but a strong order pipeline, new product launches, and regulatory-driven demand position the company for growth in FY26. Deferred revenue and order book reached new highs, with cash reserves stable at INR 190 crore.
-
Revenue grew 11% in H1 FY25, with EBITDA turning positive, driven by consumer resilience and new product launches like AntiFraud.AI. Enterprise business lagged due to delayed orders, but product diversification and R&D investment remain priorities.
-
Q1 FY25 saw 37% year-on-year revenue growth, driven by strong consumer and enterprise performance, new product launches, and robust cost management. The company is well-positioned for future growth with the DPDP Act expected to boost cybersecurity spending.